Skip to content

Givosiran sodium

Givlaari (givosiran sodium) is an oligonucleotide pharmaceutical. Givosiran sodium was first approved as Givlaari on 2019-11-20. It has been approved in Europe to treat hepatic porphyrias. Givlaari's patents are valid until 2034-10-03 (FDA).
Trade Name Givlaari
Common Name Givosiran sodium
Indication hepatic porphyrias
Drug Class
Givosiran sodium
Get full access now